Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011
Wed, February 2, 2011
Tue, February 1, 2011
Mon, January 31, 2011
Sun, January 30, 2011
Fri, January 28, 2011
Thu, January 27, 2011
Wed, January 26, 2011
Tue, January 25, 2011
Mon, January 24, 2011
Sun, January 23, 2011
Sat, January 22, 2011
Fri, January 21, 2011
Thu, January 20, 2011
Wed, January 19, 2011
Tue, January 18, 2011

Furiex Pharmaceuticals Announces Fourth Quarter 2010 Earnings Release and Conference Call


//health-fitness.news-articles.net/content/2011/ .. r-2010-earnings-release-and-conference-call.html
Published in Health and Fitness on Monday, January 31st 2011 at 5:55 GMT by Market Wire   Print publication without navigation


MORRISVILLE, N.C.--([ BUSINESS WIRE ])--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its fourth quarter 2010 financial results on Monday, February 21, 2011, after the market closes. The earnings news release will be available on the Furiex website at [ www.furiex.com ].

On Tuesday, February 22, 2011, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in:

+1 877 267 0934 (U.S./Canada)

+1 706 643 0961 (International)

Conference ID:

28925775

All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at [ www.furiex.com ]. The webcast will be archived shortly after the call for on-demand replay.

About Furiex Pharmaceuticals

Furiex Pharmaceuticals is a drug development collaboration company using innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and two products on the market. The companya™s mission is to develop innovative medicines faster and at less cost, reducing the expense of health care globally while providing life-improving therapies for patients. For more information, visit [ www.furiex.com ].


Publication Contributing Sources